Yungjin Pharm. Co., Ltd. operates as a pharmaceutical company in South Korea and internationally. The company offers cephalosporin antibiotic, antipsychotic, cardiovascular, gastrointestinal, metabolic, neuropsychiatry, respiratory, infectious, anti-inflammatory and analgesics, nutritional supplement, and urology products. It also provides vitamins, minerals, and other products; and APIs. The company was founded in 1952 and is headquartered in Seoul, South Korea. Yungjin Pharm. Co., Ltd. operates as a subsidiary of KT&G Corporation.
Research context
Yungjin Pharm. Co., Ltd appears in PyInvesting’s Korea Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- KRW
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
Yungjin Pharm. Co., Ltd is currently in a long term downtrend where the price is trading 13.1% below its 200 day moving average.
From a valuation standpoint, the stock is 38.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 5.3.
Yungjin Pharm. Co., Ltd's total revenue sank by 5.0% to $51B since the same quarter in the previous year.
Its net income has increased by 19.3% to $-2B since the same quarter in the previous year.
Finally, its free cash flow grew by 190.6% to $5B since the same quarter in the previous year.
Based on the above factors, Yungjin Pharm. Co., Ltd gets an overall score of 3/5.